profession
FDA warns of increased bone fracture risk with PPIs
NEWS IN BRIEF — Posted June 14, 2010
The Food and Drug Administration is revising prescription and over-the-counter labels for proton pump inhibitors to include safety information about a possible increased risk of fractures.
On May 25, the agency urged doctors to weigh benefits of the acid-reducing drugs against the possibility of bone fractures. The warning follows FDA review of seven epidemiological studies that reported an increased risk of fractures with the drugs.
A study in the May 10 Archives of Internal Medicine reported that postmenopausal women on PPIs had a 47% increased risk for spine fractures compared with patients not taking the drugs (link).
Note: This item originally appeared at http://www.ama-assn.org/amednews/2010/06/14/prbf0614.htm.
